According to the current clinical practice guidelines for chronic obstructive pulmonary
disease (COPD), the addition of inhaled corticosteroids (ICS) to long-acting β 2 agonist …

Background The role of inhaled corticosteroids (ICS) in chronic obstructive pulmonary
disease (COPD) has been the subject of much controversy. Major international guidelines …

Introduction As of today, there is still a need to determine which COPD patients may benefit
from ICS therapy, whether ICSs are useful in COPD patients without chronic bronchitis, and …

International guidance on chronic obstructive pulmonary disease (COPD) management
recommends the use of inhaled corticosteroids (ICS) in those patients at increased …

Context Recent studies of inhaled corticosteroid (ICS) therapy for managing stable chronic
obstructive pulmonary disease (COPD) have yielded conflicting results regarding survival …

Inhaled corticosteroids (ICS) combined with bronchodilators can reduce the frequency of
exacerbations in some patients with chronic obstructive pulmonary disease (COPD). There …

Background The benefit harm profile of inhaled corticosteroids, and their effect on patient
oriented outcomes and comorbid pneumonia, osteoporosis and cardiovascular disease in …

In this article, we focus on the scientific evidence from randomised trials supporting
treatment with inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease …

Chronic obstructive pulmonary disease (COPD) is an increasingly important public health
problem. It remains one of the leading causes of disability in developed countries and is …

The recent Towards a Revolution in COPD Health (TORCH) randomised trial replicated the
findings of previous trials in chronic obstructive pulmonary disease (COPD) on the apparent …